Details checkedStatus needs checkingCheckedcompany

AAV.103 by Regeneron

Also known as: AAV.103

Regeneron Pharmaceuticals

Primary source

Company

Regeneron Pharmaceuticals

Program Type

Therapeutic

Modality

Gene Therapy

Stage

Preclinical

Status

Unknown

Target Gene

GJB2

Route / Mode

Unknown

Confidence

78%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

genetic, congenital, pediatric, pre-lingual

Trial IDs

Mechanism

Preclinical AAV-based gene therapy program for GJB2-related congenital monogenic hearing loss; specific public technical details remain limited.

Indications

Hearing Loss Sensorineural Hearing Loss Genetic Hearing Loss

Notes

Verified as a real distinct Regeneron/Decibel preclinical AAV program for GJB2-related hearing loss. Regeneron's current public pipeline page does not list hearing-loss programs by AAV.103, so HearScape verifies existence from the acquisition disclosure while keeping public current status as Unknown.

Evidence & Sources

2 structured sources

company

Supports: canonicalName, aliases, company, allCompanies, modality, targetGene, indications, stage...

IDs: AAV.103, GJB2

Open

company

Supports: notes, status

Open

Key Events

2023-09-25

Regeneron acquisition announcement identified AAV.103 as a preclinical GJB2-related hearing-loss program